In This Section

SU2C Meg Vosburg T-Cell Lymphoma Dream Team: Tailoring CAR-based Immunotherapy Strategies to T-cell Lymphoma

Helen Heslop, MD
Leader

Helen Heslop, MD

Director
Center for Cell and Gene Therapy
Baylor College of Medicine

Gianpietro Dotti, MD
Co-leader

Gianpietro Dotti, MD

Director
Immunotherapy Program
University of North Carolina Lineberger Comprehensive Cancer Center

Research
The Dream Team is focused on developing chimeric antigen receptor (CAR)-based strategies to treat difficult-to-treat lymphomas that affect children and adults (resistant or refractory T-cell lymphoma). Finding the best combination of CARs and engineered cell types is a key goal of the Dream Team. They are poised to analyze clinical samples to identify biomarkers of response and resistance to these immunotherapies. Another key effort of the team is the development of CAR cells on an “off-the-shelf” basis so the therapy can be more available to patients, and foreseeably, less expensive

Grant News

Dream Team develops off-the-shelf CAR-T

T-cell lymphoma patient experiences long-term remission with CD30 CAR T-cell therapy